The significance of a single episode of minimal acute rejection after lung transplantation

被引:132
|
作者
Hachem, RR
Khalifah, AP
Chakinala, MM
Yusen, RD
Aloush, AA
Mohanakumar, T
Patterson, GA
Trulock, EP
Walter, MJ
机构
[1] Washington Univ, Sch Med, Div Pulm & Crit Care, St Louis, MO 63110 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA
[3] Washington Univ, Sch Med, Div Cardiothorac Surg, St Louis, MO 63110 USA
关键词
lung transplantation; minimal acute rejection; bronchiolitis obliterans syndrome;
D O I
10.1097/01.tp.0000181161.60638.fa
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Bronchiolitis obliterans syndrome (BOS) remains the leading obstacle to better long-term outcomes after lung transplantation. Acute rejection has been identified as the primary risk factor for BOS, but the impact of minimal acute rejection, especially a solitary episode, has usually been discounted as clinically insignificant. Methods. We performed a retrospective cohort study of 259 adult lung transplant recipients to determine the risk of BOS associated with a single episode of A1 rejection, without recurrence or subsequent progression to a higher grade. The cohort was divided into 3 groups based on the severity of acute rejection (none, single episode of A1, and single episode of A2). We determined the risks of BOS stages 1, 2, 3, and death for each group using univariate and multivariate Cox regression analyses. Results. A solitary episode of At rejection was a significant risk factor for BOS stages I and 2, but not stage 3 or death, in the univariate analysis. Multivariate Cox regression models confirmed that the risk of BOS attributable to a single episode of A1 rejection was independent of other potential risk factors, such as community acquired respiratory viral infections, number of HLA mismatches, and cytomegalovirus pneumonitis. Likewise, univariate and multivariate analyses demonstrated that a single episode of A2 rejection was a significant risk factor for all stages of BOS but not death. Conclusions. A single episode of minimal acute rejection without recurrence or subsequent progression to a higher grade is a significant predictor of BOS independent of other risk factors.
引用
收藏
页码:1406 / 1413
页数:8
相关论文
共 50 条
  • [41] Acute rejection after heart transplantation
    Delgado, Juan F.
    Sanchez, Violeta
    de la Calzada, Carlos S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (09) : 1139 - 1149
  • [42] Cell Free DNA Levels in Patients with Acute Rejection after Lung Transplantation
    Timofte, I.
    Keller, M.
    Varghese, A.
    Levine, D.
    Aryal, S.
    Shah, P.
    Vesselinov, R.
    Ross, D.
    Woodward, R.
    Dale, B.
    Terrin, M.
    Iacono, A.
    Agbor-Enoh, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S367 - S367
  • [43] Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantation
    van Haren, Eva
    van Vugt, Lukas K.
    Wijbenga, Nynke
    van der Sijs, Heleen
    Hellemons, Merel E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (11): : 1864 - 1868
  • [44] Acute rejection after lung transplantation: association between histopathological and CT findings
    Ambra Di Piazza
    Giuseppe Mamone
    Settimo Caruso
    Gianluca Marrone
    Fabio Tuzzolino
    Patrizio Vitulo
    Alessandro Bertani
    Roberto Miraglia
    La radiologia medica, 2019, 124 : 1000 - 1005
  • [45] The role of interleukin-17 during acute rejection after lung transplantation
    Vanaudenaerde, BM
    Dupont, LJ
    Wuyts, WA
    Verbeken, E
    Meyts, I
    Bullens, DM
    Dilissen, E
    Luyts, L
    Van Raemdonck, DE
    Verleden, GM
    EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (04) : 779 - 787
  • [46] Everolimus's Influence on Persistent Acute Rejection After Experimental Lung Transplantation
    Brunner, Elisabeth
    Lehle, Karla
    Hirt, Stephan W.
    Schmid, Christof
    von Suesskind-Schwendi, Marietta
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2013, 22 (03): : 355 - 359
  • [47] Diffuse Panbronchiolitis after Lung Transplantation. A New Form of Acute Rejection?
    Beyoglu, M. A.
    Turkkan, S.
    Sahin, M. F.
    Yazicioglu, A.
    Demirag, F.
    Yekeler, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S508 - S509
  • [48] Acute Humoral Rejection (AHR): A New Challenge after Lung Transplantation (LT)
    Neuville, M.
    Parquin, F.
    Suberbielle, C.
    Longchampt, E.
    Stern, M.
    Chapelier, A.
    Cerf, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [49] Effect of N-Acetylcysteine on Acute Allograft Rejection after Lung Transplantation
    Erne, B. V.
    Jungraithmayr, W.
    Arni, S.
    Weder, W.
    Inci, I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02): : S165 - S165
  • [50] The Role of CXCL2 in Acute Cellular Rejection after Lung Transplantation
    Novysedlak, R.
    Vachtenheim, J.
    Smetanova, J.
    Slavcev, A.
    Vychytilova, K.
    Tavandzis, J.
    Balko, J.
    Lischke, R.
    Strizova, Z.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S538 - S538